Market Overview

UPDATE: Goldman Sachs Downgrades DaVita to Neutral on Near-Term Momentum Slowdown

Share:
Related DVA
Citi Initiates DaVita Healthcare At Neutral: 'Living DaVita Loca?'
Worst Performing Industries For August 19, 2016

Goldman Sachs downgraded DaVita (NYSE: DVA) from Buy to Neutral and maintained a $120.00 price target.

Goldman Sachs noted, "We downgrade DVA to Neutral from Buy as we think the stock is now fairly valued and as we see more upside in other areas of our coverage. While our outlook for core dialysis remains solid and we continue to see strong long-term growth potential in physician (HCP) and dialysis integrated care, we expect slower growth with less upward momentum to our/Street view over the next 12-24 months."

DaVita closed at $119.21 on Thursday.

Latest Ratings for DVA

DateFirmActionFromTo
Sep 2016Raymond JamesUpgradesMarket PerformOutperform
Sep 2016Bank of AmericaDowngradesBuyNeutral
Sep 2016CitigroupInitiates Coverage onNeutral

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (DVA)

View Comments and Join the Discussion!